Indivior UK Limited

Atrix Laboratories, Inc.

Rb Pharmaceuticals Limited

Pfizer Corporation

Tolmar Therapeutics, Inc.

Mingxing Zhou

Richard L Norton

Andrew Watkins

Richard L Dunn

Bhagya L Chandrashekar

Eileen M Jarr

Mei Li

Eric Dadey

Richard W Korsmeyer

Vishwas Madhav Paralkar

Scott A Jeffers

Francis Dumont

Richard Wilker Korsmeyer

Richard Lee Dunn

Scott Alexander Jeffers

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Injectable flowable composition comprising buprenorphine

The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.

Sustained-release buprenorphine solutions

This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.

Compositions comprising buprenorphine

Injectable composition comprising buprenorphine

Injectable flowable composition buprenorphine

The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The implant may be a preformed implant, microparticles or an in situ formed implant. The implant includes a biodegradable thermoplastic polymer, the bioactive agent having a nucleophilic group substituent and a stabilizing associate as well as other optional components. The combination of the stabilizing associate with the bioactive agent prevents and/or minimizes and/or lessens degradation of the thermoplastic polymer by the bioactive agent.

Stabilized polymeric delivery system comprising a water-insoluble polymer and an organic liquid

The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of a bone growth promoting compound to certain tissues.

Controlled release polymeric compositions of bone growth promoting compounds

Growing community of inventors

Fort Collins, CO, United States of America

Mingxing Zhou